Assessment of Dose-Dependent Response to Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial

被引：0

作者：

Platzbecker, Uwe ^{[1
]}

Fenaux, Pierre ^{[2
]}

Mufti, Ghulam J. ^{[3
]}

Garcia-Manero, Guillermo ^{[4
]}

Komrokji, Rami S. ^{[5
]}

Buckstein, Rena ^{[6
]}

Diez-Campelo, Maria ^{[7
]}

Finelli, Carlo ^{[8
]}

Sekeres, Mikkael A. ^{[9
]}

Selleslag, Dominik ^{[10
]}

DeZern, Amy E. ^{[11
]}

Quesnel, Bruno ^{[12
]}

Beyne-Rauzy, Odile ^{[13
]}

Voso, Maria Teresa ^{[14
]}

Greenberg, Peter L. ^{[15
]}

Zeidan, Amer M. ^{[16
,17
]}

Ades, Lionel ^{[2
]}

Verma, Amit ^{[18
]}

Savona, Michael R. ^{[19
]}

Laadem, Abderrahmane ^{[20
]}

Ito, Rodrigo ^{[20
]}

Zhang, Jennie ^{[20
]}

Rampersad, Anita ^{[20
]}

Morison, Jessica ^{[20
]}

Louis, Chrystal ^{[20
]}

Linde, Peter G. ^{[21
]}

Santini, Valeria ^{[22
]}

机构：

[1] Univ Hosp Leipzig, Med Clin & Policlin 1, Hematol & Cellular Therapy, Leipzig, Germany

[2] Univ Paris 07, Serv Hematol Seniors, Hop St Louis, Paris, France

[3] Kings Coll London, Dept Haematooncol, London, England

[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[6] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada

[7] Univ Hosp Salamanca, Inst Biomed Res Salamanca, Hematol Dept, Salamanca, Spain

[8] S Orsola Malpighi Univ Hosp, Dept Oncol & Hematol, Bologna, Italy

[9] Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

[10] Acad Hosp St Jan, Dept Haematol, Brugge, Belgium

[11] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[12] Ctr Hosp Univ Lille, Serv Malad Sang, Hop Huriez, Lille, France

[13] Inst Univ Canc Toulouse Oncopole, Med Interne, Toulouse, France

[14] Univ Roma Tor Vergata, Dipartimento Biopatol & Diagnost Immagini, Rome, Italy

[15] Stanford Univ, Canc Ctr, Stanford, CA 94305 USA

[16] Yale Univ, Dept Internal Med, Yale Sch Med, New Haven, CT USA

[17] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[18] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, New York, NY USA

[19] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA

[20] Bristol Myers Squibb, Princeton, NJ USA

[21] Acceleron Pharma, Cambridge, MA USA

[22] Univ Florence, Azienda Osped Univ AOU Careggi, MDS Unit, Florence, Italy

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷

关键词：

MDS; clinical trial; phase III; myelodysplastic syndromes;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDS-175

引用

页码：S318 / S318

页数：1

共 50 条

[1] Assessment of dose-dependent response to luspatercept in patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the phase 3 MEDALIST trial
Platzbecker, U.
Germing, U.
Goetze, K.
Heuser, M.
Thol, F.
Fenaux, P.
Komrokji, R. S.
Laadem, A.
Ito, R.
Zhang, J.
Rampersad, A.
Morison, J.
Louis, C. U.
Giagounidis, A.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 171 - 171
[2] Effects of Luspatercept on Serum Ferritin in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial
Fenaux, Pierre
Santini, Valeria
Mufti, Ghulam J.
Diez-Campelo, Maria
Finelli, Carlo
Sekeres, Mikkael A.
Quesnel, Bruno
Beyne-Rauzy, Odile
Garcia-Manero, Guillermo
Komrokji, Rami S.
Buckstein, Rena
Voso, Maria Teresa
Selleslag, Dominik
DeZern, Amy E.
Greenberg, Peter L.
Zeidan, Amer M.
Ades, Lionel
Verma, Amit
Savona, Michael R.
Laadem, Abderrahmane
Ito, Rodrigo
Zhang, Jennie
Rampersad, Anita
Sinsimer, Daniel
Morison, Jessica
Louis, Chrystal
Linde, Peter G.
Platzbecker, Uwe
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S317 - S317
[3] Assessment of Dose-Dependent Response to Luspatercept in Patients With Lower-Risk Myelodysplastic Syndromes With Ring Sideroblasts in the Phase 3 MEDALIST Trial
不详
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 11 - 12
[4] Longer-term RBC transfusion reduction in the phase 3 MEDALIST study of luspatercept in patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS)
Platzbecker, U.
Giagounidis, A.
Heuser, M.
Goetze, K.
Thol, F.
Fenaux, P.
Komrokji, R. S.
Laadem, A.
Ito, R.
Rampersad, A.
Zhang, J.
Louis, C. U.
Germing, U.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 169 - 169
[5] Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial
Platzbecker, Uwe
Zhu, Yiming
Ha, Xianwei
Risueno, Alberto
Chan, Esther
Zhang, George
Dunshee, Diana R.
Acar, Melih
Shetty, Jeevan K.
Ito, Rodrigo
MacBeth, Kyle
Santini, Valeria
Garbowski, Maciej W.
Fenaux, Pierre
Schwickart, Martin
[J]. BLOOD, 2020, 136
[6] Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients with Lower-Risk MDS (LR-MDS) with Ring Sideroblasts (RS)
Komrokji, Rami S.
Sekeres, Mikkael A.
Zeidan, Amer M.
Fenaux, Pierre
Platzbecker, Uwe
DeZern, Amy E.
Greenberg, Peter L.
Savona, Michael R.
Jurcic, Joseph G.
Verma, Amit
Mufti, Ghulam J.
Buckstein, Rena
Santini, Valeria
Laadem, Abderrahmane
Ito, Rodrigo
Zhang, Jennie
Louis, Chrystal U.
Linde, Peter G.
Garcia-Manero, Guillermo
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S322 - S322
[7] Effects of Luspatercept on Serum Ferritin in Patients With Lower-Risk Myelodysplastic Syndromes With Ring Sideroblasts in the Phase 3 MEDALIST Trial
不详
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 17 - 18
[8] Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study
Zeidan, Amer M.
Garcia-Manero, Guillermo
DeZern, Amy E.
Fenaux, Pierre
Greenberg, Peter L.
Savona, Michael R.
Jurcic, Joseph G.
Verma, Amit
Mufti, Ghulam J.
Buckstein, Rena
Santini, Valeria
Laadem, Abderrahmane
Zhang, Jennie
Rampersad, Anita
Sinsimer, Daniel
Louis, Chrystal U.
Linde, Peter G.
Platzbecker, Uwe
Sekeres, Mikkael A.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S318 - S319
[9] Multiple periods of transfusion independence (TI) with luspatercept (LUSP) treatment (Tx) and the impact of dose escalation in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS) with ring sideroblasts (RS) from the MEDALIST study
Platzbecker, U.
Santini, V
Komrokji, R. S.
Zeidan, A. M.
Garcia-Manero, G.
Buckstein, R. J.
Oliva, E. N.
Pozharskaya, V
Nadal, J. A.
Miteva, D.
Fenaux, P.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 18 - 19
[10] Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial.
Fenaux, Pierre
Santini, Valeria
Komrokji, Rami S.
Zeidan, Amer Methqal
Garcia-Manero, Guillermo
Buckstein, Rena
Miteva, Dimana
Keeperman, Karen
Holot, Natalia
Zhang, Jennie
Hughes, Christina
Rosettani, Barbara
Yucel, Aylin
Platzbecker, Uwe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →